Koninklijke Philips (PHIA) Show & Tell 2024 summary
Event summary combining transcript, slides, and related documents.
Show & Tell 2024 summary
20 Jan, 2026Opening and agenda
The event began with a welcome, outlining a day focused on innovation, value creation, and customer engagement, including presentations, Q&A, and hands-on demos at the Customer Experience Center.
Attendees were provided with digital access to the agenda and presenter bios via QR codes.
Strategic vision and market context
The company is focused on delivering impactful, sustainable healthcare innovations, addressing both sick care and self-care.
The addressable market is expected to reach €90 billion by 2025, driven by aging populations, chronic diseases, and staff shortages, with technology positioned to bridge care gaps.
Emphasis is placed on expanding access, efficiency, and sustainability in healthcare, leveraging digital and AI advancements.
Key strategic themes
Focus on advancing precise and predictive imaging, personal health, and connected care to address growing healthcare demand and productivity pressures.
Emphasis on sustainable, people- and patient-centric innovation, with over 9% of sales invested in R&D and half of sales from recent product launches.
Execution priorities include embedding patient safety and quality, optimizing supply chains, and simplifying operating models.
ESG leadership integrated into strategy, maintaining carbon neutrality and focusing on health impact for underserved populations.
Culture shift towards impact with care, accountability, and HealthTech expertise, with significant executive renewal.
Latest events from Koninklijke Philips
- Strong margin gains and resilient performance offset flat sales and China demand weakness.PHIA
Q3 20249 Jul 2026 - All AGM proposals passed with strong support amid ongoing focus on resilience, ESG, and innovation.PHIA
AGM 20259 Jul 2026 - Margin expansion and higher free cash flow drive improved 2025 outlook despite ongoing risks.PHIA
Q2 20258 Jul 2026 - All AGM proposals passed with strong support amid focus on innovation, governance, and risk.PHIA
AGM 20268 Jul 2026 - Q3 2025 saw 8% order intake growth, 3% sales growth, and margin expansion to 12.3%.PHIA
Q3 20258 Jul 2026 - Targeting mid-single-digit growth and mid-teens margins by 2028 through AI-driven platforms and execution.PHIA
CMD 20261 Jul 2026 - Q1 2026 delivered strong sales and margin growth, with guidance reaffirmed amid global risks.PHIA
Q1 20269 May 2026 - Strong 2025 growth and margin gains set up for higher sales and profitability in 2026.PHIA
Q4 202510 Feb 2026 - Q2 saw 2% sales growth, 9% order intake rise, margin gains, and major Respironics settlements.PHIA
Q2 20242 Feb 2026